Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial.

ABSTRACT:

Importance

Since 2018, the TAILORx and RxPONDER trials have demonstrated that the 21-gene recurrence score (RS) can be indicative of the benefit of adjuvant chemotherapy in hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative breast cancer with 3 or fewer positive lymph nodes. However, its applicability to key subgroups with high risk for recurrence, including premenopausal women with positive lymph nodes and racial and ethnic minority individuals, remains unclear.

Objective

To assess the temporal patterns of and disparities in adjuvant chemotherapy use in early-stage HR-positive, ERBB2-negative breast cancer by age, genomic risk, and nodal involvement.

Design, setting, and participants

This retrospective cohort study analyzed clinical data from the 2010 to

SUBMITTER: Freeman JQ 

PROVIDER: S-EPMC12728658 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature